NCT03349073已完成1 期
An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 4
- 主要终点
- Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers Categorization of response based on RECIST 1.1.
研究概览
简要总结
T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced refractory solid tumors, and provides for a maximum of 2 cycles of treatment. At the end of 2 cycles of treatment, it is likely that some patients will be continuing to receive clinical benefit from T-1101 (Tosylate). The intention of this program is to enable these patients to continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and Taivex Therapeutics Corporation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced malignancy who are receiving T-1101 (Tosylate) in a previous Taivex Therapeutics Corp. sponsored study that has reached its endpoint, and who are, in the opinion of the investigator and/or sponsor, expected to continue to have an overall positive benefit/risk from continuing treatment.
- •Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing.
- •Women of childbearing potential who have a negative pregnancy test within 7 days of the first dose of T-1101 (Tosylate) in this long term extension trial.
- •Patients who have completed the End of Study assessments in their originating study. Every effort should be made to conduct the End of Study visit such that the patient does not have any interruption in T-1101 (Tosylate) dosing.
- •Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
排除标准
- •Any medical condition that, in the opinion of the investigator and/or sponsor, could jeopardize the safety of the patient.
- •Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- •Progressive or untreated metastatic brain or meningeal tumors.
- •Pregnancy or breastfeeding. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. Female patients must be surgically sterile or be postmenopausal, or must agree to the use of highly effective contraception during the period of therapy. Highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1 percent per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, or a vasectomized partner.
- •Substance abuse, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
研究组 & 干预措施
T-1101 (Tosylate)
Experimental
干预措施: T-1101 (Tosylate) (Drug)
结局指标
主要结局
Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers Categorization of response based on RECIST 1.1.
时间窗: Up to 2 years
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid TumorsAdvanced Refractory Solid TumorsNCT04685473Taivex Therapeutics Corporation24
终止
1 期
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid TumorsAdvanced Refractory Solid TumorsNCT03195764Taivex Therapeutics Corporation21
撤回
2 期
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT04093115Beijing Konruns Pharmaceutical Co., Ltd.
已完成
1 期
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast CancerBreast CancerNCT01325207Northwestern University34
招募中
1 期
Treatment of Moderate to Severe Refractory Crohn's DiseaseCrohns DiseaseNCT06721962Tr1X, Inc.39